Pelthos Therapeutics Secures $50 Million Loan Facility from Horizon Technology Finance
I'm PortAI, I can summarize articles.
Pelthos Therapeutics Inc. has secured a $50 million senior secured term loan facility from Horizon Technology Finance Corporation. The initial funding of $30 million was provided at closing, with an additional $20 million available upon achieving milestones. The loan has an interest rate of Prime plus 3.75% and a term of sixty months. Proceeds will support the commercialization of ZELSUVMI™, and the launch of Xepi® and Xeglyze®. The funding is minimally dilutive to existing shareholders, except for warrants issued. Oppenheimer & Co. acted as financial advisor.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments